glp-1 new drug study shows popular weight loss may slow biological aging Professor Receives Grant to Study

Description

Now, the medication has significantly narrowed that pipe, keeping you fuller for longer

While semaglutide will remain under patent in many regions until the early 2030s, the first generic versions are expected to launch in India imminently, with additional market entries anticipated in China, Canada, Brazil, Turkey, and South Africa in the months that follow

For someone struggling with GLP-1 side effects today, the most useful next step is usually to adjust the current plan, not to wait for a medication that does not yet exist

Heart Failure Benefits The most significant recent advancement has been the demonstration of profound benefits in heart failure with preserved ejection fraction (HFpEF) across multiple pivotal trials, establishing GLP-1 RAs as transformative therapy for obesity-related heart failure (Table 7)

Tirzepatide, which is sold under the brand names Mounjaro and Zepbound, significantly improves sleep apnea symptoms, according to a 2024 study published in The New England Journal of Medicine